Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.71 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14975884 | 1.00 | SYK (0.71) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL14975494 | 0.84 | SYK (0.70) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL14975493 | 0.84 | SYK (0.70) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL14955850 | 0.82 | CHEK1 (0.53) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL14955848 | 0.82 | CHEK1 (0.53) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL30261007 | 0.82 | ULK1 (0.65) | CHEK1 | |
| SCHEMBL14976992 | 0.81 | MAPK8 (0.53) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL14976362 | 0.81 | SYK (0.55) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL14981788 | 0.78 | SYK (0.71) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL14975828 | 0.77 | SYK (1.00) | SYKKCNH2MAPK3MAPK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2782580-A1 | SELECTIVE KINASE INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013078468-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | SYK, BTK, LCK | SYK 1/4885KCNH2 3642/4885MAPK3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.